Rhythm Pharmaceuticals (RYTM) Competitors $65.14 -1.25 (-1.88%) Closing price 07/8/2025 04:00 PM EasternExtended Trading$64.34 -0.80 (-1.22%) As of 04:51 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsBuy This Stock RYTM vs. ITCI, GMAB, RDY, MRNA, RGC, VTRS, QGEN, ASND, BBIO, and BPMCShould you be buying Rhythm Pharmaceuticals stock or one of its competitors? The main competitors of Rhythm Pharmaceuticals include Intra-Cellular Therapies (ITCI), Genmab A/S (GMAB), Dr. Reddy's Laboratories (RDY), Moderna (MRNA), Regencell Bioscience (RGC), Viatris (VTRS), QIAGEN (QGEN), Ascendis Pharma A/S (ASND), BridgeBio Pharma (BBIO), and Blueprint Medicines (BPMC). These companies are all part of the "pharmaceutical products" industry. Rhythm Pharmaceuticals vs. Its Competitors Intra-Cellular Therapies Genmab A/S Dr. Reddy's Laboratories Moderna Regencell Bioscience Viatris QIAGEN Ascendis Pharma A/S BridgeBio Pharma Blueprint Medicines Rhythm Pharmaceuticals (NASDAQ:RYTM) and Intra-Cellular Therapies (NASDAQ:ITCI) are both medical companies, but which is the superior investment? We will contrast the two businesses based on the strength of their earnings, institutional ownership, media sentiment, profitability, valuation, dividends, analyst recommendations and risk. Which has better earnings & valuation, RYTM or ITCI? Intra-Cellular Therapies has higher revenue and earnings than Rhythm Pharmaceuticals. Intra-Cellular Therapies is trading at a lower price-to-earnings ratio than Rhythm Pharmaceuticals, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRhythm Pharmaceuticals$130.13M31.85-$260.60M-$2.81-23.18Intra-Cellular Therapies$680.50M20.64-$139.67M-$0.73-180.64 Do analysts rate RYTM or ITCI? Rhythm Pharmaceuticals presently has a consensus target price of $78.07, suggesting a potential upside of 19.85%. Intra-Cellular Therapies has a consensus target price of $109.70, suggesting a potential downside of 16.81%. Given Rhythm Pharmaceuticals' stronger consensus rating and higher possible upside, analysts plainly believe Rhythm Pharmaceuticals is more favorable than Intra-Cellular Therapies.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Rhythm Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 14 Buy rating(s) 0 Strong Buy rating(s) 3.00Intra-Cellular Therapies 0 Sell rating(s) 10 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 2.17 Is RYTM or ITCI more profitable? Intra-Cellular Therapies has a net margin of -14.07% compared to Rhythm Pharmaceuticals' net margin of -123.26%. Intra-Cellular Therapies' return on equity of -9.93% beat Rhythm Pharmaceuticals' return on equity.Company Net Margins Return on Equity Return on Assets Rhythm Pharmaceuticals-123.26% -739.62% -44.27% Intra-Cellular Therapies -14.07%-9.93%-8.38% Do insiders and institutionals have more ownership in RYTM or ITCI? 92.3% of Intra-Cellular Therapies shares are owned by institutional investors. 6.1% of Rhythm Pharmaceuticals shares are owned by insiders. Comparatively, 2.6% of Intra-Cellular Therapies shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the media prefer RYTM or ITCI? In the previous week, Rhythm Pharmaceuticals had 10 more articles in the media than Intra-Cellular Therapies. MarketBeat recorded 11 mentions for Rhythm Pharmaceuticals and 1 mentions for Intra-Cellular Therapies. Rhythm Pharmaceuticals' average media sentiment score of 0.55 beat Intra-Cellular Therapies' score of 0.00 indicating that Rhythm Pharmaceuticals is being referred to more favorably in the media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Rhythm Pharmaceuticals 3 Very Positive mention(s) 1 Positive mention(s) 5 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Intra-Cellular Therapies 0 Very Positive mention(s) 0 Positive mention(s) 1 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Neutral Which has more risk and volatility, RYTM or ITCI? Rhythm Pharmaceuticals has a beta of 2.26, meaning that its share price is 126% more volatile than the S&P 500. Comparatively, Intra-Cellular Therapies has a beta of 0.69, meaning that its share price is 31% less volatile than the S&P 500. SummaryRhythm Pharmaceuticals beats Intra-Cellular Therapies on 9 of the 16 factors compared between the two stocks. Get Rhythm Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RYTM and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding RYTM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RYTM vs. The Competition Export to ExcelMetricRhythm PharmaceuticalsMED IndustryMedical SectorNASDAQ ExchangeMarket Cap$4.22B$2.87B$5.47B$8.95BDividend YieldN/A2.46%5.25%4.04%P/E Ratio-23.1820.8026.9620.11Price / Sales31.85286.27430.20119.79Price / CashN/A41.1936.8257.86Price / Book186.117.487.985.56Net Income-$260.60M-$55.04M$3.16B$248.40M7 Day Performance-2.66%2.44%2.39%4.67%1 Month Performance-2.37%1.90%2.18%6.64%1 Year Performance44.95%4.35%33.82%21.31% Rhythm Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RYTMRhythm Pharmaceuticals3.4426 of 5 stars$65.14-1.9%$78.07+19.9%+48.9%$4.22B$130.13M-23.18140News CoverageAnalyst ForecastITCIIntra-Cellular Therapies0.7316 of 5 stars$131.87flat$109.70-16.8%N/A$14.05B$680.50M-151.57560News CoverageGMABGenmab A/S4.0028 of 5 stars$20.52+1.1%$37.60+83.2%-16.6%$13.02B$3.12B11.662,682Analyst ForecastRDYDr. Reddy's Laboratories2.7024 of 5 stars$15.08flat$16.95+12.4%-4.7%$12.59B$325.54B22.8527,811MRNAModerna4.3762 of 5 stars$29.90-1.9%$46.61+55.9%-72.1%$11.79B$3.24B-3.425,800Gap UpRGCRegencell Bioscience0.3808 of 5 stars$18.43-19.8%N/AN/A$11.37BN/A0.0010Gap UpHigh Trading VolumeVTRSViatris2.6564 of 5 stars$9.20-1.3%$10.40+13.0%-12.7%$10.94B$14.74B-2.9032,000QGENQIAGEN3.8865 of 5 stars$47.49-1.8%$49.40+4.0%+22.3%$10.75B$1.98B119.075,765ASNDAscendis Pharma A/S3.4843 of 5 stars$175.98+1.0%$220.67+25.4%+23.2%$10.65B$393.54M-28.021,017BBIOBridgeBio Pharma4.6665 of 5 stars$43.50-1.1%$58.85+35.3%+65.2%$8.35B$221.90M-12.32400BPMCBlueprint Medicines1.5098 of 5 stars$128.40+0.0%$128.06-0.3%+10.4%$8.29B$508.82M-51.98640Insider Trade Related Companies and Tools Related Companies Intra-Cellular Therapies Competitors Genmab A/S Competitors Dr. Reddy's Laboratories Competitors Moderna Competitors Regencell Bioscience Competitors Viatris Competitors QIAGEN Competitors Ascendis Pharma A/S Competitors BridgeBio Pharma Competitors Blueprint Medicines Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RYTM) was last updated on 7/9/2025 by MarketBeat.com Staff From Our PartnersPresidential Bombshell: $150T Resource to Be Released as soon as this Summer?Something extraordinary is happening in Washington. For the first time in over a century, a sitting Preside...Paradigm Press | SponsoredINVESTOR ALERT: Tiny “$3 AI Wonder Stock” on the Verge of Blasting OffRight now, we’re witnessing a monumental shift in the world.Traders Agency | SponsoredGoogle did what!?!?A new technology has sparked a modern-day gold rush in Silicon Valley. OpenAI’s Sam Altman invested $375M. Bil...Stansberry Research | SponsoredElon’s NEXT Big IPO?Cancel your internet TODAY!? Take your latest internet bill and light it on fire… then count the seconds it...Banyan Hill Publishing | Sponsored3..2..1.. AI 2.0 ignition (don’t sleep on this)I just put together an urgent new presentation that you need to see right away. In short: I believe we are...Timothy Sykes | SponsoredBuffett’s $325 Billion Cash Problem — Solved by Gold?A bombshell announcement is just weeks away — and it could send shockwaves through the gold market. Most inves...Golden Portfolio | SponsoredElon’s RevengeElon Musk and President Trump's new feud is all over the news... But what no one has reported – yet – is th...Altimetry | SponsoredHedge fund legend humiliates Bitcoin tradersLarry Benedict made $274 million trading on Wall Street… Barron’s ranked his hedge fund in the top 1% world...Brownstone Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Rhythm Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Rhythm Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
